Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$509.20 USD

509.20
976,366

+0.48 (0.09%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $509.02 -0.18 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (163 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain Hologic (HOLX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Hologic (HOLX) on the back of its continued strength in the Breast Health arm.

Catalent (CTLT) Expands Facility Capabilities in Shanghai

by Zacks Equity Research

Catalent's (CTLT) latest capability expansion is expected to boost its business in the clinical trials space in its Asia-Pacific Clinical Supply Services network.

Masimo (MASI) Announces Positive Study Results on PBM by SpHb

by Zacks Equity Research

Masimo's (MASI) SpHb is likely to enhance transfusion management and post-operative patient outcomes on patients.

Merit Medical (MMSI) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Merit Medical's (MMSI) slew of product launches.

Cooper Companies (COO) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Cooper Companies' (COO) fiscal fourth-quarter results are likely to reflect segmental strength.

Zacks Investment Ideas feature highlights: McKesson, Cardinal Health and Super Micro Computer

by Zacks Equity Research

McKesson, Cardinal Health and Super Micro Computer are part of the Zacks Investment Ideas article.

Derek Lewis headshot

3 Stocks Silently Outperforming Energy in 2022

by Derek Lewis

Outperforming the Zacks Oils and Energy sector in 2022 is no easy task. However, bulls have silently roamed in all three of these stocks, breaking the overall bearish trend we've become accustomed to.

Henry Schein's (HSIC) New Tie-Up to Improve Patient Outcome

by Zacks Equity Research

Henry Schein's (HSIC) recent deal with VideaHealth is expected to aid dentists in proving greater transparency to patients, thus making better treatment recommendations and improving case acceptance.

Here's Why You Should Hold on to Nevro (NVRO) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Nevro (NVRO), owing to its strength in the global SCS market.

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) continues to gain from solid product portfolio despite forex woes.

McKesson (MCK) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

McKesson (MCK) possesses solid growth attributes, which could help it handily outperform the market.

Here's Why You Should Hold OPKO Health (OPK) Stock For Now

by Zacks Equity Research

OPKO Health (OPK) is likely to gain from the potential in RAYALDEE that targets a growing market coupled with new collaborations and acquisitions.

Merit Medical (MMSI) Launches New Inflation Device basixALPHA

by Zacks Equity Research

Merit Medical (MMSI) launches basixALPHA inflation device in the United States for one-handed preparation and fast inflation with minimal exertion to streamline angioplasty procedures.

AmerisourceBergen (ABC) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about AmerisourceBergen's (ABC) strength in its World Courier business.

Boston Scientific (BSX) Posts Positive Post-Market Study Data

by Zacks Equity Research

The latest PMCF study demonstrates that Boston Scientific's (BSX) ACURATE neo2 Aortic Valve System is expected to significantly improve patient outcomes.

QIAGEN's (QGEN) New Monkeypox Test to Aid Faster Identification

by Zacks Equity Research

QIAGEN's (QGEN) latest multiplex test is expected to strengthen its portfolio and boost its fight against the global monkeypox outbreak.

Here's Why You Should Retain Stryker (SYK) Stock For Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on it.

Zacks.com featured highlights include Archer-Daniels-Midland, McKesson, ParkerHannifin, Booz Allen Hamilton and Darden Restaurants

by Zacks Equity Research

Archer-Daniels-Midland, McKesson, ParkerHannifin, Booz Allen Hamilton and Darden Restaurants are part of the Zacks Screen of the Week article.

Alcon's (ALC) Latest Buyout to Enhance Its Product Portfolio

by Zacks Equity Research

Alcon's (ALC) ophthalmic pharmaceutical product suite is expected to be significantly boosted by adding new products following the recent acquisition.

Here's Why You Should Retain Cardinal Health (CAH) Stock Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.

3 Reasons to Retain QIAGEN (QGEN) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about QIAGEN (QGEN) on the back of a series of product launches.

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Alcon (ALC) Q3 Earnings Surpass Estimates, Sales Guidance Cut

by Zacks Equity Research

Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the strength in its comprehensive portfolio of PCIOLs, including PanOptix and Vivity.

Here's Why You Should Add McKesson (MCK) Stock Right Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

The Zacks Analyst Blog Highlights Archer-Daniels-Midland, McKesson, Marathon Petroleum, Exxon Mobil and Merck & Co

by Zacks Equity Research

Archer-Daniels-Midland, McKesson, Marathon Petroleum, Exxon Mobil and Merck & Co are part of the Zacks top Analyst Blog.